John Baird, M.D.
Duarte Cancer Center
Duarte, CA 91010
Hematology
Medical Oncology
Internal Medicine
2013, M.D., University of Arkansas for Medical Sciences, Little Rock, AR
2008, B.S., Biomedical Engineering, Washington University, St. Louis, MO
2020-2021, Fellow, Blood and Marrow Transplantation, Stanford Hospital & Clinics, Palo Alto, CA
2019-2020, Postdoctoral Fellow, Cancer Cellular Therapies, Stanford University, Palo Alto, CA
2016-2019, Fellow, Hematology and Medical Oncology, Stanford Hospital & Clinics, Palo Alto, CA
2014-2016, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
2013-2014, Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
2021-Present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2023 CIRM CLIN2 Grant, City of Hope
2022 Lymphoma SPORE Career Enhancement Award, City of Hope
2020, Abstract Achievement Award, American Society of Hematology
2019, NIH T32 Institutional Training Grant, Stanford, Department of BMT
2013, Richard V. Ebert Award, UAMS, Department of Internal Medicine
2013, Graduated with Honors in Research, UAMS
2012, Class of 1949 Scholarship, UAMS
2012, Clinical Research Training Program Fellow, NIH-OCRTME
2011, Alpha Omega Alpha, UAMS
2010, Barton Foundation Scholarship, UAMS
2010, Dr. George S. Wise Memorial Scholarship, UAMS
2009, Class of 1954 Scholarship, UAMS
2009, Medical Student Research Program in Diabetes, NIDDK
2008, Medical Alumni Association Scholarship, UAMS
2008, Dorothy Snider Foundation Scholarship, UAMS
2003, Eagle Scout, Bronze and Gold Eagle Palms, BSA QAC Troop 7
American Association for Cancer Research
American Society of Hematology
American Society for Transplantation and Cellular Therapy
American Society of Clinical Oncology
CIBMTR Infection and Immune Reconstitution Working Group
American College of Physicians
- Frank MJ*, Baird JH*, et al.: “CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy.” N Engl J Med. 2023; in submission.
- Ong SY, Baird JH: “A primer on chimeric antigen receptor T-cell therapy-related toxicities for the intensivist.” J Intensive Care Med. 2023; accepted.
- Ong SY, Pak S, Mei M…Baird JH, et al.: “Bendamustine is a well-tolerated alternative to fludarabine as lymphodepletion for standard of care CD19-directed chimeric antigen receptor (CAR) T-cell therapy.” Am J Hematol. 2023; accepted.
- Nie EH, Su YJ, Baird JH, et al.: “Radiographic and clinical correlatives associated with immune effector cell-associated neurotoxicity syndrome (ICANS) after CD19 CAR T-cell therapy for mantle cell lymphoma.” Neuro-Oncology. 2023; in submission.
- Harris CE, Vijenthira A, Ong SY…Baird JH: “COVID-19 and other viral infections in patients with hematologic malignancies.” Am Soc Clin Oncol Educ Book. 2023; 43:e390778.
- Ladbury C, Dandapani S…Baird JH, et al.: “Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed/refractory large B-cell lymphoma.” Cancers (Basel). 2023; 15(6):1747.
- Sworder BJ, Kurtz DM, Alig SKC…Baird JH, et al.: “Determinants of resistance to engineered T-cell therapies targeting CD19 in large B-cell lymphomas.” Cancer Cell. 2022; 41(1):210-225.e5.
- Good Z, Spiegel JY, Sahaf B…Baird JH, et al.: “Post-infusion TReg-like CAR T cells identify patients resistant to CD19-CAR therapy.” Nat Med. 2022; 28(9):1860-71.
- Rainone M, Ngo D, Baird JH, et al.: “Emapalumab for CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis.” Blood Adv. 2023; 7(4):533-36.
- Baird JH, Frank MJ, Craig J, et al.: “CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma.” Blood. 2021; doi: 10.1182/blood.2020009432.
- Spiegel JY, Patel S, Muffly L, Hossain N, Oak J, Baird JH, et al.: “CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.” Nat Med. 2021; 27(8):1419-31
- Johnsrud AJ, Craig J, Baird JH, et al. “Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T cell therapy.” Blood Adv. 2021; doi: 10.1182/bloodadvances.2021004716.
- Baird JH, Epstein DJ, Tamaresis JS, et al.: “Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma.” Blood Adv. 2021; 5(1):143-55.
- Van Vuren AJ, Minniti CP, Mendelsohn L, Baird JH, et al.: “Lactate dehydrogenase to carboxyhemoglobin ratio as a biomarker of heme release to heme processing is associated with higher tricuspid regurgitant jet velocity and early death in SCD.” Am J
- Baird JH, Gotlib J, George TI, et al.: “A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.” Blood Adv. 2019 Aug 13;3(15):2264-2271.
- Baird JH, Gotlib J: “Clinical validation of KIT inhibition in advanced systemic mastocytosis.” Curr Hematol Malig Rep. 2018 Oct;13(5):407-416.
- Baird JH, Minniti CP, Lee JM, Tian X, et al.: “Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide.” Br. J. Haematol. 2015; 168(5):737-46. 7.
- Baird JH, Frey N, Birnbaum B, Porter DL: “Voriconazole-induced periostitis after allogeneic stem cell transplantation.” Am. J. Hematol. 2015; 90(6):574-5.
- Lodhi IJ, Yin L, Coleman T, Baird JH, et al.: “Targeted inhibition of adipose lipogenesis decreases obesity and insulin resistance by disrupting PPAR-γ activation.” Cell Metab. 2012; 16(2):189-201.